Inventiva (NASDAQ:IVA) Upgraded at Truist Financial

Truist Financial upgraded shares of Inventiva (NASDAQ:IVA) to a strong-buy rating in a report published on Wednesday,Zacks.com reports.

A number of other research firms have also recently weighed in on IVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research report on Thursday, January 22nd. UBS Group started coverage on shares of Inventiva in a report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 target price for the company. Leerink Partners started coverage on shares of Inventiva in a report on Monday, January 12th. They set an “outperform” rating and a $12.00 price target on the stock. Barclays began coverage on shares of Inventiva in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 price objective on the stock. Finally, HC Wainwright set a $24.00 price target on Inventiva and gave the stock a “buy” rating in a report on Wednesday, January 28th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $16.56.

Inventiva Price Performance

Shares of NASDAQ IVA opened at $5.78 on Wednesday. The business’s 50 day moving average is $6.30 and its two-hundred day moving average is $5.36. Inventiva has a 1-year low of $2.70 and a 1-year high of $7.98.

Institutional Investors Weigh In On Inventiva

A number of hedge funds have recently added to or reduced their stakes in IVA. Wealth Enhancement Advisory Services LLC grew its holdings in shares of Inventiva by 55.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 25,770 shares of the company’s stock worth $142,000 after purchasing an additional 9,212 shares during the last quarter. Creative Planning purchased a new position in Inventiva during the 2nd quarter valued at about $32,000. Commonwealth Equity Services LLC increased its stake in shares of Inventiva by 19.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock worth $361,000 after purchasing an additional 12,704 shares in the last quarter. Virtu Financial LLC purchased a new position in Inventiva in the 4th quarter valued at about $60,000. Finally, XTX Topco Ltd acquired a new stake in shares of Inventiva during the fourth quarter worth $84,000. 19.06% of the stock is currently owned by institutional investors and hedge funds.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.